Stock listing
NASDAQ:AVLN Avalyn Pharma Inc. Stock
Home listing (NASDAQ) of Avalyn Pharma Inc.
Follow Avalyn Pharma Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:AVLN
$28.40 USD +0.71 (+2.6%)
Close on Nov 20, 2026
- Day range
- $27.85 – $29.38 USDNov 20, 2026
- Volume
- 214,295 sharesNov 20, 2026
- Market cap
- $1.26B USDAt the close on Nov 20, 2026 · price × 44.33M shares outstanding
- Traded on an average day
- $10.04M USDMedian day 286,743 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:AVLN · Home | $28.40 USD | +0.71 (+2.6%) | 214,295 | $28.06 | $29.38 | $27.85 | $27.69 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:AVLN · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $28.40 | +0.71 | +2.6% | $28.06 | $29.38 | $27.85 | 214,295 | |
| $27.69 | -0.23 | -0.8% | $27.74 | $29.08 | $27.29 | 404,890 | |
| $27.92 | -1.84 | -6.2% | $29.76 | $29.76 | $27.04 | 453,013 | |
| $29.76 | -0.52 | -1.7% | $30.28 | $30.62 | $29.15 | 329,069 | |
| $30.28 | -0.31 | -1.0% | $30.57 | $30.84 | $29.30 | 574,888 | |
| $30.59 | -1.03 | -3.3% | $30.78 | $31.39 | $28.15 | 499,880 | |
| $31.62 | +0.45 | +1.4% | $31.07 | $31.87 | $30.67 | 474,481 | |
| $31.17 | +1.67 | +5.7% | $29.16 | $31.51 | $28.71 | 478,189 | |
| $29.50 | +0.35 | +1.2% | $29.75 | $30.74 | $28.56 | 796,771 | |
| $29.15 | +2.48 | +9.3% | $26.71 | $29.18 | $26.13 | 630,263 | |
| $26.67 | -0.80 | -2.9% | $27.58 | $27.97 | $26.26 | 476,339 | |
| $27.47 | +0.66 | +2.5% | $27.70 | $28.35 | $26.03 | 455,275 | |
| $26.81 | +1.21 | +4.7% | $25.87 | $26.96 | $25.45 | 450,174 | |
| $25.60 | -0.03 | -0.1% | $25.63 | $26.44 | $25.10 | 445,062 | |
| $25.63 | -0.08 | -0.3% | $25.71 | $26.17 | $24.85 | 343,494 | |
| $25.71 | -0.03 | -0.1% | $26.09 | $26.20 | $25.17 | 593,264 | |
| $25.74 | -0.09 | -0.3% | $25.68 | $26.74 | $24.82 | 1,085,546 | |
| $25.83 | -1.31 | -4.8% | $27.00 | $27.19 | $25.28 | 961,285 | |
| $27.14 | +1.10 | +4.2% | $26.20 | $28.30 | $25.48 | 411,020 | |
| $26.04 | -1.21 | -4.4% | $27.21 | $27.21 | $25.43 | 320,312 | |
| $27.25 | +2.14 | +8.5% | $25.12 | $27.57 | $25.10 | 286,743 | |
| $25.11 | +0.48 | +1.9% | $24.74 | $25.57 | $22.99 | 209,634 | |
| $24.63 | +1.30 | +5.6% | $23.33 | $24.75 | $22.24 | 217,518 | |
| $23.33 | -0.33 | -1.4% | $23.95 | $24.30 | $23.07 | 180,005 | |
| $23.66 | -0.98 | -4.0% | $24.72 | $24.72 | $23.53 | 291,400 | |
| $24.64 | +0.95 | +4.0% | $23.88 | $25.14 | $23.59 | 199,400 | |
| $23.69 | -0.05 | -0.2% | $23.69 | $24.15 | $22.68 | 267,800 | |
| $23.74 | -1.06 | -4.3% | $24.66 | $25.27 | $23.08 | 403,900 | |
| $24.80 | -0.96 | -3.7% | $25.64 | $25.93 | $24.70 | 133,300 | |
| $25.76 | +0.04 | +0.2% | $25.70 | $26.33 | $25.22 | 241,800 | |
| $25.72 | +0.19 | +0.7% | $25.32 | $25.82 | $24.14 | 883,800 | |
| $25.53 | +0.10 | +0.4% | $25.30 | $26.31 | $25.26 | 202,900 | |
| $25.43 | -1.60 | -5.9% | $27.22 | $27.22 | $25.06 | 260,600 | |
| $27.03 | -1.10 | -3.9% | $27.98 | $28.21 | $26.26 | 427,300 | |
| $28.13 | +0.71 | +2.6% | $28.59 | $28.92 | $27.72 | 526,200 | |
| $27.42 | -1.07 | -3.8% | $28.48 | $28.69 | $26.86 | 423,600 | |
| $28.49 | +1.39 | +5.1% | $27.05 | $29.00 | $26.57 | 347,600 | |
| $27.10 | -1.22 | -4.3% | $27.67 | $28.67 | $27.01 | 422,000 | |
| $28.32 | +0.24 | +0.9% | $27.92 | $28.80 | $27.27 | 205,900 | |
| $28.08 | -0.47 | -1.6% | $28.52 | $28.53 | $27.00 | 223,100 | |
| $28.55 | -1.12 | -3.8% | $29.70 | $30.16 | $27.40 | 221,200 | |
| $29.67 | -2.78 | -8.6% | $32.19 | $32.54 | $29.14 | 252,000 | |
| $32.45 | +0.83 | +2.6% | $31.94 | $33.18 | $31.00 | 233,300 | |
| $31.62 | +0.10 | +0.3% | $31.34 | $33.00 | $30.97 | 177,300 | |
| $31.52 | -1.91 | -5.7% | $33.15 | $34.04 | $31.18 | 664,800 | |
| $33.43 | -1.28 | -3.7% | $35.26 | $35.46 | $31.77 | 317,000 | |
| $34.71 | +0.43 | +1.3% | $34.38 | $35.20 | $34.10 | 244,500 | |
| $34.28 | -0.70 | -2.0% | $35.01 | $35.53 | $32.59 | 227,200 | |
| $34.98 | +1.41 | +4.2% | $33.40 | $36.42 | $33.40 | 494,100 | |
| $33.57 | -1.10 | -3.2% | $35.15 | $35.39 | $33.56 | 132,900 | |
| $34.67 | -1.21 | -3.4% | $35.26 | $36.18 | $34.22 | 129,100 | |
| $35.88 | -1.74 | -4.6% | $37.30 | $37.69 | $35.60 | 168,600 | |
| $37.62 | +0.23 | +0.6% | $37.15 | $38.70 | $36.81 | 302,175 | |
| $37.39 | +1.95 | +5.5% | $35.21 | $38.34 | $34.90 | 243,500 | |
| $35.44 | -0.14 | -0.4% | $35.85 | $36.34 | $34.37 | 150,900 | |
| $35.58 | +0.30 | +0.9% | $35.29 | $36.21 | $34.62 | 181,900 | |
| $35.28 | +0.55 | +1.6% | $34.63 | $35.82 | $34.31 | 183,600 | |
| $34.73 | +0.04 | +0.1% | $34.52 | $35.61 | $34.22 | 333,100 | |
| $34.69 | -1.82 | -5.0% | $36.45 | $36.45 | $34.37 | 202,900 | |
| $36.51 | -0.53 | -1.4% | $36.82 | $37.52 | $36.19 | 129,000 | |
| $37.04 | -1.16 | -3.0% | $38.02 | $38.37 | $36.39 | 142,600 | |
| $38.20 | +0.51 | +1.4% | $37.99 | $39.11 | $37.87 | 108,400 | |
| $37.69 | -0.68 | -1.8% | $38.49 | $38.96 | $36.63 | 158,400 | |
| $38.37 | +1.24 | +3.3% | $37.13 | $39.68 | $37.06 | 159,500 | |
| $37.13 | -1.84 | -4.7% | $38.65 | $39.57 | $36.70 | 179,300 |
- Ticker
- NASDAQ:AVLN
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 12, 2026
Avalyn Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Latest deck · September 2026
Investor Presentation (September 2026)
Investor deck · 37 slides
Latest news
Avalyn Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Nov 12, 2026
Closed $30.59 (-3.3%) on Nov 12, 2026
Avalyn to Present at Upcoming Investor Conferences
Nov 3, 2026
Closed $26.81 (+4.7%) on Nov 3, 2026
Avalyn Appoints Robert J. Meyer, MD, to its Board of Directors
Sep 16, 2026
Closed $33.43 (-3.7%) on Sep 17, 2026
Avalyn to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Sep 8, 2026
Closed $37.62 (+0.6%) on Sep 8, 2026
Avalyn Presents New Data at ERS Congress 2026 Supporting AP01 Lung Distribution and Patient-Centered Trial Design in Pulmonary Fibrosis
Sep 8, 2026
Closed $37.62 (+0.6%) on Sep 8, 2026
Avalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026
Aug 24, 2026
Closed $38.20 (+1.4%) on Aug 25, 2026
Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Aug 12, 2026
Closed $37.38 (+5.4%) on Aug 12, 2026
Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary Fibrosis
Jun 17, 2026
Closed $29.31 (+4.4%) on Jun 17, 2026
Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights
Jun 3, 2026
Closed $26.40 (+2.6%) on Jun 3, 2026
Avalyn to Participate in the Jefferies Global Healthcare Conference
May 27, 2026
Closed $26.82 (+0.4%) on May 27, 2026
Avalyn Pharma Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 16 in the last 12 months · 16 in all · newest Nov 12, 2026 · oldest 2026
- Decks
- 2 decks · latest September 2026
Where Avalyn Pharma Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:AVLN · Home listing · This page | NASDAQ | United States | USD |
| BOATS:AVLN | BOATS | United States | USD |
Valuation
Price/book 3.4× against a median of 3.3×: 5th lowest of 9 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $946.4M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 3.4×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 0.12
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Avalyn Pharma Inc. · NASDAQ:AVLN | US$1.26B | US$946.4M | n/a | n/a | n/a | 3.4× | n/a | 0.0× | 0.12 |
| OliX Pharmaceuticals, Inc. · KRX:226950 | US$1.31B | US$1.17B | n/a | 114× | n/a | 7.4× | −102.9% | 0.1× | n/a |
| Absci Corporation · NASDAQ:ABSI | US$1.30B | US$1.13B | n/a | 758× | n/a | 5.9× | n/a | 0.0× | 3.20 |
| LB Pharmaceuticals Inc · NASDAQ:LBRX | US$1.26B | US$858.7M | n/a | n/a | n/a | 3.0× | n/a | 0.0× | 0.81 |
| MannKind Corporation · NASDAQ:MNKD | US$1.24B | US$1.46B | n/a | 3.5× | 309× | n/a | −18.1% | n/a | 1.06 |
| Novavax, Inc. · NASDAQ:NVAX | US$1.23B | US$902.3M | n/a | 2.2× | n/a | n/a | −18.6% | n/a | 1.98 |
| Silence Therapeutics PLC · NASDAQ:SLN | US$1.23B | US$984.6M | n/a | 2,159× | n/a | 5.7× | n/a | 0.0× | 1.07 |
| Ocular Therapeutix, Inc. · NASDAQ:OCUL | US$1.23B | US$774.9M | n/a | 15.4× | n/a | 2.8× | −648.6% | 0.2× | 1.35 |
| Generate Biomedicines, Inc. · NASDAQ:GENB | US$1.22B | US$895.6M | n/a | 28.1× | n/a | 3.2× | −637.0% | 0.2× | 1.90 |
| Taysha Gene Therapies, Inc. · NASDAQ:TSHA | US$1.21B | US$837.4M | n/a | 153× | n/a | 3.4× | n/a | 0.1× | 1.69 |
| Mineralys Therapeutics, Inc. · NASDAQ:MLYS | US$1.21B | US$585.1M | n/a | n/a | n/a | 2.4× | n/a | 0.0× | 1.39 |
| Median of the others | US$1.23B | US$899.0M | 71.3× | 309× | 3.3× | −102.9% | 0.1× | 1.39 |
Forecasts
3 strong buy · 2 buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 61.80 USD · Analysts' mean
- EPS, year to Dec 2026
- -2.69 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Heather Turner | Board Chair CEO, LB Pharma |
| Lyn Baranowski | Chief Executive Officer |
| Doug Carlson | Chief Financial Officer and Chief Business Officer |
| Melissa Rhodes | Chief Operating Officer |
| Adam Golden | General Counsel and Head of Business Development |
| Kelly Donoghue | Sr. Manager, IR and Corporate Communications |
| Craig Conoscenti | Senior Vice President, Clinical Development |
| Frank Salisbury | Senior Vice President, Commercial |
| Jill Denning | Senior Vice President, Clinical Development Operations |
| Jim Bishop | Senior Vice President, Business Operations |
| Kimberley Cummings | SENIOR VICE PRESIDENT, REGULATORY AFFAIRS |
| Stephen Pham | Senior Vice President, Product Development |
| David Friedman | MANAGING DIRECTOR AND SENIOR ANALYST, Suvretta Capital Management |
| Howard M. Lazarus | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| Heather Turner | Board Chair CEO, LB Pharma |
| Jill Carroll | Partner, SR One |
| Lyn Baranowski | Chief Executive Officer |
| Robert J. Meyer | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 · Before open | −3.3% |
| Q2 2026 | Aug 12, 2026 · Before open | +5.4% |
| Q1 2026 | Jun 3, 2026 · Before open | +2.6% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2026) | Investor deck | 37 slides | September 2026 |
| Technical Presentation (September 2023) | Technical | 12 slides | Sep 11, 2023 |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Closed: US$345M raised · US$18 a share · Morgan Stanley +3 Dealers: Morgan Stanley (co-lead), Jefferies (co-lead), Evercore ISI (co-lead), Guggenheim Securities (co-lead) | May 1, 2026 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$18.00 a share on Apr 29, 2026.
- Price
- US$18.00 a share
- Shares offered
- 16,666,667 shares of common stock
- Offering size
- US$300 million
- Underwriters' option
- Up to 2,500,000 more shares
- Listing
- AVLN on the Nasdaq Global Select Market
- Underwriters
- Morgan Stanley, Jefferies, Evercore ISI, Guggenheim Securities · In the order on the cover
- Shares delivered
- On or about May 1, 2026
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Feb 6, 2026 |
| Filed publicly | Apr 8, 2026 |
| Amended twice | Newest Apr 29, 2026 |
| Shares registered with an exchange | Apr 27, 2026 |
| Declared effective by the SEC | Apr 29, 2026 |
| Final prospectus, with the price | Apr 30, 2026 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Apr 30, 2026 |
| EFFECT · Notice that a registration is effective | Apr 29, 2026 |
| CERT · Exchange's certificate of listing | Apr 29, 2026 |
| S-1/A · Registration statement, amended | Apr 29, 2026 |
| 8-A12B · Registration of shares for listing on an exchange | Apr 27, 2026 |
| S-1/A · Registration statement, amended | Apr 23, 2026 |
| S-1 · Registration statement | Apr 8, 2026 |
| DRS/A · Draft registration statement, amended | Mar 18, 2026 |
| DRS · Draft registration statement | Feb 6, 2026 |
Open IPO · From the cover of the final prospectus (424B4) filed Apr 30, 2026
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | 0 | 0 |
| Research and development | 76.6M | 45.8M |
| Selling, general and administrative | 14.7M | 11.4M |
| Operating income | -91.3M | -57.1M |
| Depreciation and amortization | 42.0K | 29.0K |
| EBITDA | -91.3M | -57.1M |
| Income before tax | -85.2M | -49.7M |
| Net income | -85.2M | -49.7M |
| Earnings per share, basic | -2.04 | -1.19 |
Balance sheet
| Line | FY2025 | FY2024 |
|---|---|---|
| Cash and equivalents | 52.3M | 24.0M |
| Short-term investments | 86.0M | 86.7M |
| Receivables | 537.0K | 591.0K |
| Current assets | 143.6M | 114.4M |
| Total assets | 148.9M | 124.5M |
| Accounts payable | 3.76M | 2.28M |
| Current liabilities | 14.1M | 8.74M |
| Total debt | 1.67M | |
| Total liabilities | 387.5M | 299.0M |
| Shareholders' equity | -238.7M | -174.5M |
| Shares outstanding | 41.8M | 41.8M |
Cash flow
| Line | FY2025 | FY2024 |
|---|---|---|
| Cash from operations | -81.5M | -48.4M |
| Capital spending | -344.0K | -95.0K |
| Free cash flow | -81.8M | -48.5M |
| Cash from investing | 10.1M | -91.5M |
| Cash from financing | 99.8M | 89.0K |
| Change in cash | 28.4M | -139.8M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 19, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 17, 2026 | Other filings | SEC |
| 4 · Change in ownership | Nov 12, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
All 74 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 12, 2026 | Results | SEC |
| 4 · Change in ownership | Sep 17, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 17, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 16, 2026 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 11, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 6, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jul 1, 2026 | Material contract | SEC |
| 8-K · Current report | Jun 17, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Jun 3, 2026 | Quarterly report | SEC |
| 8-K · Current report | Jun 3, 2026 | Results | SEC |
| SCHEDULE 13D · Big-stake notice | May 8, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D · Big-stake notice | May 8, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 7, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | May 5, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | May 5, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | May 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2026 | Insider trade | SEC |
| 8-K · Current report | May 1, 2026 | Current report | SEC |
| S-8 · Registration statement for employee plans | Apr 30, 2026 | Offer document | SEC |
| 424B4 · Prospectus | Apr 30, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Apr 30, 2026 | Other filings | SEC |
| 3 · Initial statement of ownership | Apr 29, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 29, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 29, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 29, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 29, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 29, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 29, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 29, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 29, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 29, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 29, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 29, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 29, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 29, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 29, 2026 | Insider trade | SEC |
| CERT · Exchange's certificate of listing | Apr 29, 2026 | Other filings | SEC |
| S-1/A · Registration statement, amended | Apr 29, 2026 | Offer document | SEC |
| 8-A12B · Registration of shares for listing on an exchange | Apr 27, 2026 | Other filings | SEC |
| S-1/A · Registration statement, amended | Apr 23, 2026 | Offer document | SEC |
| S-1 · Registration statement | Apr 8, 2026 | Offer document | SEC |
| DRS/A · Draft registration statement, amended | Mar 18, 2026 | Offer document | SEC |
| DRS · Draft registration statement | Feb 6, 2026 | Offer document | SEC |
| D | Oct 10, 2023 | Other filings | SEC |
| D | May 7, 2020 | Other filings | SEC |
| D/A | May 24, 2017 | Other filings | SEC |
| D | Mar 24, 2017 | Other filings | SEC |
| D/A | Aug 12, 2015 | Other filings | SEC |
| D/A | Mar 24, 2015 | Other filings | SEC |
| D | Nov 16, 2012 | Other filings | SEC |
Cap table
Built by 6ix from Avalyn Pharma Inc.’s releases · as of Aug 31, 2026
- Common shares
- 44,333,095
- Fully diluted
- 44,333,095
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 44,333,095 | Aug 31, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Aug 31, 2026 | 44,333,095 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Heather Turner Other companies: LB Pharmaceuticals Inc (Chief Executive Officer, Director · Since at least Sep 10, 2025); Terns Pharmaceuticals, Inc. (Director · Since at least Nov 18, 2024); Lyell Immunopharma, Inc. (Chief General Counsel · Jun 16, 2021 – Mar 16, 2022 · Past); Sangamo Therapeutics, Inc. (EVP, General Counsel & Sec. · Feb 12, 2018 – Feb 25, 2019 · Past); Atara Biotherapeutics, Inc. (Former EVP, GC & Sec. · Feb 6, 2018 – Feb 9, 2018 · Past) | Director · Since at least Apr 29, 2026 |
| Erin Lavelle Other companies: Jade Biosciences, Inc. (Director · Since at least Apr 28, 2025); Neurogene Inc. (Director · May 12, 2022 – Jun 8, 2023 · Past); Climb Bio, Inc. (COO & CFO · Aug 9, 2021 – Oct 31, 2022 · Past); Alder BioPharmaceuticals Inc (Chief Operating Officer · Apr 16, 2018 – Oct 22, 2019 · Past) | Director · Since at least Apr 29, 2026 |
| Douglas R Carlson Other companies: ImageneBio, Inc. (COO & EVP of Finance · Mar 25, 2021 – Mar 25, 2021 · Past); Collegium Pharmaceutical, Inc. (VP Corp. Devlp · May 6, 2015 – May 6, 2015 · Past) | See Remarks · Since at least Apr 29, 2026 |
| Jill Carroll Other companies: Arcellx Inc (Director · Since at least Feb 3, 2022); Pandion Therapeutics Inc (Director · Apr 1, 2021 – Apr 1, 2021 · Past) | Director · Since at least Apr 29, 2026 |
| Jon Congleton Other companies: Immunic, Inc. (Director · Since at least Mar 27, 2026); Mineralys Therapeutics, Inc. (Chief Executive Officer, Director · Since at least Feb 9, 2023) | Director · Since at least Apr 29, 2026 |
| Jon Congleton Other companies: Mineralys Therapeutics, Inc. (Chief Executive Officer · Since at least Oct 2, 2026); Immunic, Inc. (Independent Director · Since at least May 13, 2026) | Since at least Apr 6, 2026 |
| Robert J. Meyer Other companies: Chimerix Inc (Director · Jun 20, 2024 – Apr 21, 2025 · Past) | Director · Since at least Sep 15, 2026 |
| Adam Golden | General Counsel and Head of Business Development · Since at least Jun 3, 2026 |
| Craig Conoscenti | Senior Vice President, Clinical Development · Since at least May 21, 2026 |
| David Friedman | MANAGING DIRECTOR AND SENIOR ANALYST, Suvretta Capital Management · Since at least Nov 5, 2026 |
All 21 people
| Person | Seat |
|---|---|
| Doug Carlson | Chief Financial Officer and Chief Business Officer · Since at least Nov 4, 2026 |
| Frank Salisbury | Senior Vice President, Commercial · Since at least Jun 3, 2026 |
| Howard M. Lazarus | Chief Medical Officer · Since at least Apr 29, 2026 |
| Jill Denning | Senior Vice President, Clinical Development Operations · Since at least Nov 4, 2026 |
| Jim Bishop | Senior Vice President, Business Operations · Since at least Nov 4, 2026 |
| Kate Haviland | Since at least Nov 4, 2026 |
| Kelly Donoghue | Sr. Manager, IR and Corporate Communications · Since at least Nov 3, 2026 |
| Kimberley Cummings | SENIOR VICE PRESIDENT, REGULATORY AFFAIRS · Since at least Nov 5, 2026 |
| Lyn Baranowski | Chief Executive Officer · Since at least Sep 16, 2026 |
| Melissa Rhodes | Chief Operating Officer · Since at least Apr 29, 2026 |
| Stephen Pham | Senior Vice President, Product Development · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Avalyn Pharma Inc.